Capricor Soars on Positive Phase 3 HOPE-3 Trial Results for their Duchenne Muscular Dystrophy (DMD) Study

Capricor Therapeutics (NASDAQ: CAPR) announced significant positive topline results from its pivotal Phase 3 HOPE-3 clinical trial. The study evaluated Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), meeting its primary endpoint and a key secondary cardiac endpoint with statistical significance. These results signal a potential paradigm shift in the treatment of DMD, particularly for its devastating effects on skeletal and cardiac muscle.

The data reveals that Deramiocel achieved a clinically meaningful and statistically significant slowing of disease progression. For investors, this outcome positions Capricor to potentially address a prior Complete Response Letter (CRL) from the FDA, leveraging the HOPE-3 data as substantial evidence of the therapy’s efficacy and safety. The market has responded favorably to the news, reflecting renewed confidence in Deramiocel’s path toward regulatory approval.

HOPE-3 Trial: A Definitive Outcome

The HOPE-3 study was a randomized, double-blind, placebo-controlled Phase 3 trial involving 106 boys and young men with DMD across 20 U.S. clinical sites. Participants, with an average age of approximately 15 years, received intravenous infusions of either Deramiocel (150 million cells per infusion) or a placebo every three months over a 12-month period.

Key efficacy results from the trial underscore the therapeutic potential of Deramiocel:

• Primary Endpoint (Skeletal Function): The study met its primary endpoint, measured by the Performance of the Upper Limb (PUL v2.0) total score. Patients treated with Deramiocel showed a 54% slowing of disease progression compared to the placebo group, with a p-value of 0.029. This result is particularly noteworthy as it demonstrates a substantial preservation of upper limb function, which is critical for maintaining independence and quality of life in patients who are often non-ambulatory.
• Key Secondary Endpoint (Cardiac Function): The trial also achieved its key secondary cardiac endpoint, measured by Left Ventricular Ejection Fraction (LVEF). The Deramiocel cohort experienced a 91% slowing in the decline of cardiac function versus placebo (p=0.041). Given that cardiomyopathy is the leading cause of mortality in DMD, this finding is a significant advancement.

Dr. Linda Marbán, CEO of Capricor, stated, “These results reinforce the durable benefits seen in HOPE-2 and its open-label extension… We believe these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position us to address the clinical issues in the Complete Response Letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval.”

Strategic Implications for Investors

The positive outcome of the HOPE-3 trial carries substantial strategic implications for Capricor Therapeutics and its investors. The statistically significant results provide a solid foundation for the company’s upcoming Biologics License Application (BLA) resubmission.

Addressing Regulatory Hurdles

The primary strategic advantage of these results is their potential to resolve the issues raised in the FDA’s previous CRL. With prior alignment from the FDA suggesting that positive HOPE-3 data could be sufficient for approval, Capricor now possesses the pivotal evidence needed to make a compelling case for Deramiocel. A successful BLA resubmission could lead to market approval, transforming Deramiocel from an investigational therapy into a commercial-stage asset.

First-in-Class Potential

Deramiocel is positioned as a potential first-in-class therapy designed to treat both skeletal and cardiac manifestations of DMD. Its unique mechanism of action, which involves immunomodulatory and anti-fibrotic effects, differentiates it from existing treatments that often focus on specific aspects of the disease. The preservation of both upper limb and heart function addresses a major unmet need, particularly in the largely non-ambulatory patient population studied in the trial.

Long-Term Value and Market Opportunity

DMD affects approximately 15,000 individuals in the U.S. alone. As a designated Orphan Drug with Regenerative Medicine Advanced Therapy (RMAT) status, Deramiocel could qualify for a Priority Review Voucher upon approval. This voucher can be sold to other companies, providing a non-dilutive source of capital. The successful development and commercialization of Deramiocel would establish Capricor as a leader in rare disease therapeutics and unlock significant long-term value for shareholders.

Understanding Deramiocel and DMD

Duchenne muscular dystrophy is a severe X-linked genetic disorder characterized by the absence of functional dystrophin, a protein essential for muscle cell integrity. This leads to progressive muscle degeneration, affecting skeletal, respiratory, and heart muscles. Ultimately, heart failure from cardiomyopathy becomes the primary cause of mortality.

Deramiocel consists of allogeneic cardiosphere-derived cells (CDCs), which have demonstrated potent immunomodulatory and anti-fibrotic properties. These cells act by secreting exosomes that modulate the immune response, shifting it toward a healing phenotype rather than a pro-inflammatory one. This mechanism helps preserve muscle function and structure.

The therapy has already received several key designations from regulatory bodies:

• Orphan Drug Designation from the FDA and European Medicines Agency (EMA).
• Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S.
• Advanced Therapy Medicinal Product (ATMP) designation in Europe.
• Rare Pediatric Disease Designation from the FDA.

Looking Ahead for Capricor

With the strength of the HOPE-3 data, Capricor Therapeutics is moving forward with its regulatory strategy. The company plans to submit its response to the CRL, incorporating the new results in its BLA submission. The favorable safety and tolerability profile observed in the trial, consistent with prior studies, further strengthens its case.

As Dr. Craig McDonald, the National PI of the HOPE-3 trial, noted, “A nearly 54 percent slowing of skeletal muscle disease progression is extraordinary in Duchenne and directly linked to maintaining independence and quality of life.” This sentiment, combined with the positive cardiac data, highlights the profound clinical impact Deramiocel could have. For investors, the successful completion of the HOPE-3 trial marks a critical de-risking event and a major step toward realizing the commercial potential of this innovative cell therapy.

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com.